Other function: specific glycan targeting to eradicate cancer stem cells

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201400027C
Awardee
Awarding agency
Obligated
$222,319

Award facts

Opportunity
  • N43CO4100527 Solicitation number
Contract value 100% obligated
$222,319.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 27 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Waban, MA 02468, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $222,319

About this award

Written by GovTribe AI ·

This is a Definitive Contract awarded by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Siamab Therapeutics, Inc. for "OTHER FUNCTION: SPECIFIC GLYCAN TARGETING TO ERADICATE CANCER STEM CELLS". The contract is a Firm Fixed Price arrangement with a ceiling value of $222,319.00 and an ultimate completion date of January 11, 2016. The contract was awarded on September 12, 2014 and was not set aside for a specific business type.

Quick answers

Who was awarded contract HHSN261201400027C?

HHSN261201400027C was awarded to Siamab Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 12, 2014.

How much is contract HHSN261201400027C worth?

The government has obligated $222,319 on HHSN261201400027C.

Was contract HHSN261201400027C competed?

The extent of competition for HHSN261201400027C was full and open competition. The government received 27 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login